Abstract
Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge for cancer research. In this review, we highlight the emerging experimental strategies for blocking KRAS function and signaling and its direct targeting. We also report on the results in this field of research produced by our group.
| Original language | English |
|---|---|
| Article number | 57 |
| Journal | Journal of Experimental and Clinical Cancer Research |
| Volume | 37 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Mar 13 2018 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Targeting kras in metastatic colorectal cancer : Current strategies and emerging opportunities. / Porru, Manuela; Pompili, Luca; Caruso, Carla; Biroccio, Annamaria; Leonetti, Carlo.
In: Journal of Experimental and Clinical Cancer Research, Vol. 37, No. 1, 57, 13.03.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Targeting kras in metastatic colorectal cancer
T2 - Current strategies and emerging opportunities
AU - Porru, Manuela
AU - Pompili, Luca
AU - Caruso, Carla
AU - Biroccio, Annamaria
AU - Leonetti, Carlo
PY - 2018/3/13
Y1 - 2018/3/13
N2 - Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge for cancer research. In this review, we highlight the emerging experimental strategies for blocking KRAS function and signaling and its direct targeting. We also report on the results in this field of research produced by our group.
AB - Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge for cancer research. In this review, we highlight the emerging experimental strategies for blocking KRAS function and signaling and its direct targeting. We also report on the results in this field of research produced by our group.
UR - http://www.scopus.com/inward/record.url?scp=85043602156&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043602156&partnerID=8YFLogxK
U2 - 10.1186/s13046-018-0719-1
DO - 10.1186/s13046-018-0719-1
M3 - Article
AN - SCOPUS:85043602156
VL - 37
JO - Journal of Experimental and Clinical Cancer Research
JF - Journal of Experimental and Clinical Cancer Research
SN - 0392-9078
IS - 1
M1 - 57
ER -